The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with intermediate or advanced-stage hepatocellular carcinoma (HCC) after failure of systemic therapy recommended by BCLC.
Has a diagnosis of HCC confirmed by radiology, histology, or cytology;
Barcelona Clinic Liver Cancer (BCLC) stage C with the presence of portal vein tumor thrombus;
Has received previous systemic therapy recommended for HCC by BCLC, and the systemic therapy failed;
Both PD-1inhibitors and Lenvatinib patients received only include marketed drugs but are not limited to HCC approval;
The interval between the failure of systemic therapy and the beginning of combination therapy longer than 3 months;
With other malignant tumors;
Unable to meet criteria of combination timeframe described above.
First Hospital of China Medical University
Lead sponsor